In Trial 6, adolescent patients with moderate‑to‑severe atopic dermatitis not adequately controlled with topical prescription treatments were randomized to DUPIXENT or placebo. Adolescents ≥60 kg received DUPIXENT 300 mg Q2W following a 600 mg loading dose, while adolescents <60 kg received 200 mg Q2W following a 400 mg loading dose. The primary endpoint was the change from baseline to Week 16 in the proportion of subjects with an Investigator's Global Assessment (IGA) of 0 (clear) or 1 (almost clear) and ≥2‑point improvement.1,2
(IGA 0 or 1)
Baseline:IGA 4 (severe)
Week 16:IGA 2 (mild)
Actual 12-year-old patient in the phase 3 adolescent DUPIXENT trial. Patient had a baseline IGA of 4 and EASI of 31. Individual results may vary.
A clinical responder was defined as a patient achieving IGA 0 or 1 and at least a 2-point
improvement from baseline1